FDA approval for skin cancer cream

3M has received an "approvable" letter from the U.S. Food and Drug Administration (FDA) in response to its supplemental new drug application on Aldara (imiquimod) Cream, 5% for the treatment of superficial basal cell carcinoma (sBCC), a common form of non-melanoma skin cancer.

The FDA noted no major deficiencies in the application and requested 3M provide additional safety data as a condition of approval. 3M plans to submit such additional data from completed clinical studies shortly. Given that FDA review of the additional data will take up to six months, 3M now expects potential approval in the second half of 2004.

Last month, the FDA approved Aldara cream as a treatment option for certain patients with actinic keratosis (AK), a pre-cancerous skin disease caused by cumulative sun exposure. The response from dermatologists since 3M launched Aldara cream as an AK treatment option has been favorable.

Aldara cream is the first and only patient-applied immune response modifier and is available by prescription only. Full prescribing information is available at www.3M.com/Aldara.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study uncovers why targeted therapy fails in some non-small cell lung cancer patients